Search Results


Your search for Elihu H. Estey, MD,Elihu H. Estey, MD matches 4 pages

Showing 1 - 4

AML Pioneer and ‘Gentle Soul,’ Elihu H. Estey, MD, Dies at 75

“A lot of times, younger bright physicians are afraid to say what they really think, out of fear of challenging the dogma. One of the things I do when mentoring is to ask why we are doing a particular therapy or intervention. I tell my mentees not to let the data interfere with your knowledge,”...

Expert Point of View: Steven Gore, MD, Eyten Stein, MD, and Elihu H. Estey, MD

In discussions after these presentations, several points were made by several experts. To begin, Steven Gore, MD, Director of Hematologic Malignancies at Yale Medical School, called the study of venetoclax plus 10-day decitabine “very important,” but he raised the issue of appropriate dosing. He...


Expert Point of View: Elihu H. Estey, MD; Steven Gore, MD; and Mark J. Levis, MD, PhD

ELIHU H. ESTEY, MD, Professor of Medicine at the University of Washington and Director of Acute Myeloid Leukemia (AML) Clinical Research at the Fred Hutchinson Cancer Research Center, Seattle, added that with these “robust” outcomes, future trial patients may “not be eager to wind up in the...

Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?

USING THE National Cancer Database, Bhatt et al1 recently reported that of the 61,775 adults with acute myeloid leukemia (AML), those who received chemotherapy from 2003 to 2011 lived longer than those who, in those same years, did not; the study is reviewed in this issue of The ASCO Post....